top of page

Lung cancer

Confirm Trial
2021
Lung - Mesothelioma
CHECKMATE 743 trial, ipi/nivo for mesothelioma
2021
Lung - Mesothelioma
Impower 133
2018
Lung - SCLC
CASPIAN
2021
Lung - SCLC
PROFILE 1014 trial, crizot vs chemo
2014
Lung NSCLC - ALK
ASCEND-4 trial, cerit vs chemo
2017
Lung NSCLC - ALK
Alex trial, alect vs crizo
2017
Lung NSCLC - ALK
ALTA-1L , briga vs crizo
2018
Lung NSCLC - ALK
Crown trial, lorla vs crizo
2020
Lung NSCLC - ALK
FLAURA trial
2018
Lung NSCLC - EGFR
ADAURA trial, adjuvant Osimertinib
2020
Lung NSCLC - EGFR
Docetaxel in second line
2000
Lung NSCLC - advanced
Pemetrexed in recurrent advanced NSCLC
2004
Lung NSCLC - advanced
Scagliotti trial
2008
Lung NSCLC - advanced
REVEL trial
2014
Lung NSCLC - advanced
KEYNOTE-024
2016
Lung NSCLC - advanced
KEYNOTE-407
2018
Lung NSCLC - advanced
KEYNOTE-189
2018
Lung NSCLC - advanced
KEYNOTE-042
2019
Lung NSCLC - advanced
CheckMate 227
2019
Lung NSCLC - advanced
MYSTIC trial
2020
Lung NSCLC - advanced
Impower110 trial
2020
Lung NSCLC - advanced
CheckMate 9LA trial
2021
Lung NSCLC - advanced
IMPOWER 010 trial, adj atezo
2021
Lung NSCLC - perioperative

Confirm Trial
Fennell DA et al, Lancet Onc, 2021, PMID: 34656227

Lung - Mesothelioma

Background. Phase 3 RCT included 332 patients who have previously been treated with two prior lines of chemotherapy in 2:1 ratio

 

Arm A: Nivolumab 240 mg every 2 weeks
Arm B: Placebo

 

Primary Endpoint: PFS, OS
Median follow up: 5.09 mo

 

mPFS: 3.0 mo vs 1.8 mo, arm a vs b respectively, HR 0.67, 95% CI 0.53–0.85, P=.0012
mOS: 10.2 mo vs 6.9 mo, HR 0.69, 95% CI 0.52–0.91, P=.0090

 


Adverse events. Serious adverse events occurred in 41% vs 44%, including dyspnoea (8% vs 9%), pneumonia (6% vs 5%) and lower respiratory tract infection (4% vs 7%).

 

Conclusions. Nivolumab improved PFS and OS when compared to placebo amongst patients with malignant pleural or peritoneal mesothelioma previously treated with two prior lines of chemotherapy.

 

Summarized by Pragnan Kancharla, MD

 

Send a feedback

 

bottom of page